企業プロフィール
Zura Bio 株価・ニュース・カタリスト
- ティッカー:
- ZURA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
5.68 USD (+1.97%)
終値
最終更新: 2026年8月17日
389M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ZURA closed up 1.97% at $5.68. No new same-company headline was identified in the current news window.
企業概要
Autoimmune and Inflammatory Diseases
Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules.
Tibulizumab
Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in chronic immune-mediated disease.
TibuSHIELD
The Phase 2 TibuSHIELD study evaluates tibulizumab in adults with hidradenitis suppurativa, an inflammatory skin disease driven in part by IL-17 signaling.
TibuSURE
The Phase 2 TibuSURE study evaluates tibulizumab in adults with systemic sclerosis, where simultaneous IL-17 and BAFF inhibition may address inflammation, autoantibodies, and fibrosis.
NEXUS-PMR
Zura selected polymyalgia rheumatica as a third indication for tibulizumab. The planned Phase 2 NEXUS-PMR study extends the program into an inflammatory disorder commonly treated with long-term glucocorticoids.
今後のカタリスト
- Topline data from the Phase 2 TibuSHIELD study in the fourth quarter of 2026.
- Initiation of the Phase 2 NEXUS-PMR study by the end of 2026.
- Topline data from the Phase 2 TibuSURE study in the first half of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。